This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Genta Gets Drug Trial Boost

Shares of Genta (GNTA) surged more than 20% after the cancer-drug developer said regulators agreed to the design of a proposed trial for its experimental leukemia treatment.

The Food and Drug Administration completed a special protocol assessment of the proposed trial, which will enroll patients with symptomatic chronic lymphocytic leukemia who have not previously received chemotherapy.

The trial will compare the results of patients who receive the chemotherapy drug fludarabine plus Genentech's (DNA) Rituxan with and without Genta's treatment, Genasense.

Last month, an FDA oncology drug advisory committee voted against approving a new drug application for Genasense. Although the FDA isn't required to follow the advice of its advisory committee, it often does. A decision from the FDA is expected Oct. 29.

The trial supporting the company's application involved a combination of the chemotherapies fludarabine plus cyclophosphamide with or without Genasense in patients with CLL whose condition has gotten worse.

"We are pleased that the FDA had no outstanding issues regarding the design or analysis of this trial, and also with the agency's agreement that there were no safety issues that precluded the use of Genasense in previously untreated patients," said Genta's CEO Dr. Raymond Warrell.

Warrell says the company will not decide on whether to go through with the trial until the company has met with the FDA to review the status of its drug application.

The stock gained 20.1% to 96 cents in premarket trading Friday. More recently, shares were trading up 7 cents, or 9.4%, at 88 cents.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs